Evolus to Participate in Barclays 2020 Global Healthcare Conference

An audio webcast of Evolus presentation will be available on the investor relations section of Evolus website atinvestors.evolus.com.Replays of the webcasts will be available for 90 days after the date of the presentation.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Tuesday, March 3, 2020

Information

Tags:

Drugs, Articles, Telecommunications, Daewoong Pharmaceutical, Brand management, Product management, Botulinum toxin, Trademark, Pharmaceutics, Webcast

Geotags:

Organisation:

EVOLUS

Summary

Key Points:

An audio webcast of Evolus presentation will be available on the investor relations section of Evolus website atinvestors.evolus.com.Replays of the webcasts will be available for 90 days after the date of the presentation.
Evolusis a performance beauty company with a customer-centric approach focused on delivering breakthrough products.
Food and Drug Administrationapproved Jeuveau (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure technology.
Jeuveau is a registered trademark of Evolus, Inc.
Hi-Pure is a trademark of Daewoong Pharmaceutical Co, Ltd.

NEWPORT BEACH, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that management will be participating in the Barclays 2020 Global Healthcare Conference in Miami, Florida.


		Event:		Barclays 2020 Global Healthcare Conference
		Format:		Fireside chat & 1x1 Meetings
		Date:		Wednesday, March 11, 2020
		Time:		3:20 – 3:45pm ET
		Location:		Loews Miami Beach Hotel, Miami Beach, Florida

An audio webcast of Evolus’ presentation will be available on the investor relations section of Evolus’ website at investors.evolus.com. Replays of the webcasts will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure^™ technology. Jeuveau^® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.

Jeuveau^® is a registered trademark of Evolus, Inc.

Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor Contact:
Ashwin Agarwal, Evolus, Inc.
Vice President, Finance, Investor Relations & Treasury
Tel: +1-949-284-4559
Email: [email protected]

Media Contact:
Crystal Muilenburg, Evolus, Inc.
Vice President, Corporate Communications & Public Relations
Tel: +1-949-284-4506
Email: [email protected]